[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Pan CC, Lee WL: Vaginal obliteration in a woman with a history of cutaneous T-cell lymphoma: the results of combined chemotherapy-induced gonadal toxicity and lymphoma relapse. Taiwan J Obstet Gynecol; 2010 Mar;49(1):69-71
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal obliteration in a woman with a history of cutaneous T-cell lymphoma: the results of combined chemotherapy-induced gonadal toxicity and lymphoma relapse.
  • OBJECTIVE: Although ovarian failure commonly occurs following chemotherapy, the relation between menopause or related sexual activity in this failure is often overlooked.
  • CASE REPORT: A 42-year-old married woman with a history of Mayer-Rokitansky-Küster-Hauser syndrome, an established neovagina, and complete clinical remission of cutaneous T-cell lymphoma (stage T4) treated with bleomycin, cyclophosphamide, doxorubicin, vincristine and prednisolone had suffered from abdominal pain.
  • Imaging studies (computed tomography) and laboratory evaluations indicating a suspicious pelvic abscess with leukocytosis (16,800/mm(3)) and elevated serum C-reactive protein (18.4 mg/L) levels.
  • The patient underwent intensive medical treatment and surgical intervention, but died 2 months later.
  • Pathology showed widespread lymphoma throughout the perineal area, including the neovagina, deep pelvic cavity and the entire abdominal cavity.
  • CONCLUSION: Physicians should be greatly concerned about the frequency and severity of treatment-associated acute and long-term complications, such as gonadal toxicity.
  • In this case, vaginal obliteration was an early sign of tumor recurrence, although menopause may have contributed to the vaginal obliteration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, T-Cell, Cutaneous / pathology. Neoplasm Recurrence, Local. Surgically-Created Structures. Vagina / surgery. Vaginal Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20466296.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


2. Sokołowska-Wojdyło M, Trzeciak M, Roszkiewicz J: 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma. Dermatol Reports; 2010 Aug 31;2(2):e12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma.
  • The primary cutaneous lymphomas are often indolent but difficult to treat.
  • In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking.
  • The purine analog 2-chlorodeoxyadenosine (2CdA) acts in non-Hodgkin's lymphoma and has been used in our center for the treatment of advanced primary cutaneous T-cell lyphomas (CTCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386249.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211472
  • [Keywords] NOTNLM ; 2-chlorodeoxyadenosine (2CdA) / Sézary syndrome / cutaneous T-cell lymphoma / mycosis fungoides / side effect. / treatment
  •  go-up   go-down


3. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res; 2007 Apr 15;13(8):2318-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
  • PURPOSE: To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL).
  • EXPERIMENTAL DESIGN: Data from 1 single-arm, open-label, multicenter pivotal trial and 11 other trials submitted to support the new drug application for vorinostat in the treatment of advanced primary CTCL were reviewed.
  • RESULTS: The pivotal trial enrolled 74 patients with stage IB or higher CTCL.
  • Median number of prior treatments was 3, and 61 patients (82%) had stage IIB or higher disease.
  • The objective response rate in the skin disease assessed by change in the overall SWAT score from the baseline was 30% (95% CI, 18.5 to 42.6) in patients with stage IIB or higher disease.
  • Median time to tumor progression was 148 days for overall population and 169 days for patients with stage IIB or higher disease.
  • Vorinostat was approved for treatment of cutaneous manifestations of CTCL.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Animals. Cats. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Dogs. Humans. Neoplasm Staging. Patient Selection. Pruritus / drug therapy. Pruritus / etiology. Skin / drug effects. Skin / pathology. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438089.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


Advertisement
4. Kiratli H, Gümüs K: [Mycosis fungoides of the eyelids. Two case reports]. J Fr Ophtalmol; 2006 Mar;29(3):323-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mycosis fungoides of the eyelids. Two case reports].
  • [Transliterated title] Mycosis fongoïde des paupières. A propos de deux cas.
  • Mycosis fungoides is a distinct variant of cutaneous T cell lymphoma.
  • We describe two male patients presenting with the third stage of the disease at the age of 56 and 67 years.
  • Multiagent chemotherapy and PUVA treatment were administered with limited successful outcome on their cutaneous lesions.
  • These two cases demonstrate the poor prognosis of the tumor stage because of strong association with widespread systemic involvement and emphasize the need for early diagnosis.
  • [MeSH-major] Eyelid Neoplasms. Mycosis Fungoides. Skin Neoplasms

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557179.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol; 2006 Mar;126(3):575-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
  • Denileukin diftitox (Ontak), a recombinant fusion protein of diphtheria toxin and ligand, IL-2, binds to the IL-2 receptor, is internalized, and causes cell death.
  • Denileukin diftitox was approved for the treatment of cutaneous T-cell lymphomas (CTCLs) with CD25+ expression.
  • We prospectively stained lesional skin biopsy specimens from 113 mycosis fungoides and Sézary Syndrome patients for activation markers CD25 and CD30 to correlate expression with clinical tumor-node metastasis (TNM) stage, histologic grade, and response to denileukin diftitox.
  • Advanced TNM (T3 or T4) was significantly associated with intermediate-grade (P = 0.002) and large-cell transformation histology (P = 0.04).
  • These data suggest that high CD25 expression by IHC is associated with advanced CTCL and with clinical response to denileukin diftitox therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Receptors, Interleukin-2 / analysis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD30 / analysis. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Recombinant Fusion Proteins / therapeutic use. Skin / pathology. Tetrahydronaphthalenes / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410787.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815; United States / NCI NIH HHS / CA / R21-CA74117
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 25E79B5CTM / denileukin diftitox; A61RXM4375 / bexarotene; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


6. Quéreux G, Renaut JJ, Peuvrel L, Knol AC, Brocard A, Dréno B: Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol; 2010 Nov;90(6):616-20
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
  • Psoriasis is thought to be associated with an increased risk of lymphoma.
  • We report here the first case of an aggressive primary cutaneous pleomorphic T-cell lymphoma in a patient with psoriasis.
  • A biopsy confirmed a stage IVa primary cutaneous pleomorphic T-cell lymphoma.
  • Despite treatment with pegylated liposomal doxorubicin, the disease progressed and the patient died 5 months later.
  • This case of pleomorphic T-cell lymphoma was remarkable in both its extremely rapid onset and the aggressive nature of the disease.
  • The onset of this disease in a patient with psoriasis who had been previously treated with immunosuppressive drugs and a tumour necrosis factor (TNF)-α blocker is of major interest.
  • Only eight cases of cutaneous lymphomas associated with treatment with TNF-α blockers have been published previously.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Lymphoma, T-Cell, Cutaneous / chemically induced. Psoriasis / drug therapy. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Biopsy. Cyclosporine / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etanercept. Fatal Outcome. Humans. Immunoglobulin G / adverse effects. Leg. Male. Methotrexate / adverse effects. Neoplasm Invasiveness. Neoplasm Staging. Polyethylene Glycols / therapeutic use. Receptors, Tumor Necrosis Factor. Treatment Failure

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057746.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; OP401G7OJC / Etanercept; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist; 2007 Oct;12(10):1247-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
  • Food and Drug Administration granted regular approval to vorinostat (Zolinza(R); Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.
  • The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).
  • Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sézary syndrome.
  • The median duration of protocol treatment was 118 days.
  • The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estimated median response duration was 168 days, and the median time to tumor progression was 202 days.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Approval. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Histone Deacetylase Inhibitors. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome. United States. United States Food and Drug Administration


8. Wollina U, Hohaus K, Schönlebe J, Haroske E, Köstler E: Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases. J Cancer Res Clin Oncol; 2003 Jan;129(1):65-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases.
  • PURPOSE: Advanced cutaneous T-cell lymphoma (CTCL) is a hard-to-treat condition.
  • The use of liposomal formulation anti-cancer drugs can improve the efficacy and the risk-benefit ratio.
  • Liposomal doxorubicin was shown to be effective as a second-line treatment in CTCL.
  • METHODS: Monotherapy with liposomal-encapsulated daunorubicin (DNX) was given as a monotherapy once a month at 20 mg/m(2) three times to achieve a clinical response.
  • In the case of limited response the drug was given once every 3 weeks and a dose increase was performed.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Daunorubicin / administration & dosage. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Administration Schedule. Female. Humans. Liposomes. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jul 1;92(1):7-14 [11443603.001]
  • [Cites] Pharmacotherapy. 2000 Oct;20(10):1221-3 [11034047.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):901-5 [11453809.001]
  • [Cites] Oncol Nurs Forum. 1998 Jan-Feb;25(1):67-70 [9460774.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):499-505 [9516942.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):40-6 [10607318.001]
  • [Cites] Invest New Drugs. 1997;15(3):247-53 [9387047.001]
  • [Cites] Invest New Drugs. 1999;17(1):81-7 [10555126.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):691-5 [10942057.001]
  • [Cites] Curr Oncol Rep. 2001 Mar;3(2):156-62 [11177748.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1045-61 [11772234.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):457-62 [11398876.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(1):15-21 [11221955.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):128-34 [11216914.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):323-8 [11531287.001]
  • [Cites] Lancet. 1996 Mar 30;347(9005):871-6 [8622396.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):89-98 [11699226.001]
  • [Cites] Histopathology. 2000 Feb;36(2):136-44 [10672058.001]
  • (PMID = 12618903.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Wobser M, Göppner D, Lang SC, Beckmann G, Flentje M, Ugurel S, Bröcker EB, Becker JC: Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox. Arch Dermatol; 2010 Jul;146(7):805-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / therapy. Remission Induction / methods. Skin Neoplasms / therapy
  • [MeSH-minor] Aged, 80 and over. Dose-Response Relationship, Drug. Follow-Up Studies. Foot. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Recombinant Fusion Proteins / administration & dosage. Recombinant Fusion Proteins / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644054.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


10. Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L: Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. Clin Lymphoma Myeloma; 2009 Oct;9(5):E21-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.
  • Mycosis fungoides is the most common subtype of mature T-cell lymphoma that primarily arises in the skin.
  • The tumor manifests as patches, plaques, tumors, or erythroderma and can secondarily involve lymph nodes, peripheral blood, and visceral organs.
  • In advanced tumor stage, chemotherapy is a second-line approach, which is generally not considered curative.
  • Initially, most patients profit from this treatment, but observed remissions usually do not exceed several months.
  • Because of possible immunosuppressive effects in vulnerable patients, the overall benefit of chemotherapy itself is not unequivocal in cutaneous T-cell lymphoma.
  • We report 3 patients whose tumor-stage mycosis fungoides was not sufficiently controlled by several preceding systemic therapies, including liposome-encapsulated doxorubicin.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858049.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J: Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci; 2001 Sep;941:147-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival.
  • Nine patients with mycosis fungoides (age range 27-67) underwent autologous peripheral blood stem cell transplantation (PBSCT).
  • All patients had tumor-stage disease, and four had lymph node involvement.
  • Eight patients exhibited a peripheral blood T cell clone using PCR/SSCP analysis of the TCR gamma gene, six prior to harvest and two at the time of harvest.
  • Conditioning prior to reinfusion of stem cells was achieved with various combinations of total skin electron beam (TSEB), total body irradiation (TBI), and chemotherapy, depending upon the patient's prior exposure to radiotherapy.
  • Those with a short DFS were distinguished by rapid tumor onset prior to transplant but not by stage at transplant.
  • Loss of a detectable T cell clone after manipulation of the harvest did not discriminate between the two groups, but rapid relapsers had been subjected to a greater degree of T cell depletion, possibly indicating a compromised cytotoxic response post-PBSCT.
  • The median survival of the cohort is four years from tumor onset, 15 months from PBSCT, and 27 months from the date a peripheral blood clone was first detected in the presence of tumor-stage disease.
  • Our data demonstrate the value of PBSCT for inducing remission in tumor-stage mycosis fungoides.
  • Reinfusion of neoplastic cells could be avoided by harvesting stem cells at an earlier stage in the disease process, preferably before a T cell clone is detectable in the peripheral blood.
  • Alternatively T cell depletion should be restricted to the CD4 subset.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Mycosis Fungoides / mortality. Mycosis Fungoides / therapy. Skin Neoplasms / mortality. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease-Free Survival. Genes, T-Cell Receptor gamma. Humans. Lymphocyte Depletion. Middle Aged. Remission Induction. Risk Factors. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594568.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Steinhoff M, Beyer M, Roewert-Huber J, Lukowsky A, Assaf C, Sterry W: Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol; 2008 May;58(5 Suppl 1):S88-91
Hazardous Substances Data Bank. Fenofibrate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
  • Mycosis fungoides and its variants are a distinct entity with a variable, but well-characterized clinical course.
  • We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
  • We hypothesize that combination of the high-dose fenofibrate (400 mg) with the retinoid X receptor ligand bexarotene and vorinostat might have induced an increased rate of apoptosis in lymphoma cells in our patient resulting in an extensive release of lymphoma antigens.
  • [MeSH-major] Fenofibrate / administration & dosage. Granuloma / chemically induced. Hydroxamic Acids / administration & dosage. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy. Tetrahydronaphthalenes / adverse effects
  • [MeSH-minor] Acute Disease. Anticarcinogenic Agents / administration & dosage. Anticarcinogenic Agents / adverse effects. Biopsy. Drug Eruptions / pathology. Female. Fever / chemically induced. Humans. Hypolipidemic Agents / administration & dosage. Middle Aged. Necrosis. Remission Induction. Skin / pathology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489056.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Hydroxamic Acids; 0 / Hypolipidemic Agents; 0 / Tetrahydronaphthalenes; 58IFB293JI / vorinostat; A61RXM4375 / bexarotene; U202363UOS / Fenofibrate
  •  go-up   go-down


13. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol; 2001 May;144(5):1010-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
  • BACKGROUND: The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukaemia.
  • OBJECTIVES: To test the efficacy of this combination in 12 patients with cutaneous T-cell lymphoma (CTCL).
  • METHODS: Nine patients with erythrodermic CTCL were identified for the study, eight of whom met the criteria for Sézary syndrome (SS), and three with tumour-stage mycosis fungoides (MF).
  • Six patients had treatment withdrawn, five due to bone marrow suppression and one due to progressive disease.
  • No difference in pretrial parameters were found in those who had treatment withdrawn and those who tolerated at least three courses.
  • As with other multiagent chemotherapy regimens, bone marrow toxicity is a common and severe side-effect.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Mycosis Fungoides / drug therapy. Pilot Projects. Sezary Syndrome / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11359390.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


14. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol; 2002 Oct;138(10):1359-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.
  • BACKGROUND: Allogeneic hematopoietic stem cell transplantation has proved to be an effective therapeutic option in various hematologic neoplastic disorders.
  • Because patients with advanced cutaneous T-cell lymphoma have a poor prognosis, with minimal possibilities of sustained remission, we studied the therapeutic potential of hematopoietic stem cell transplantation.
  • OBSERVATIONS: Three young patients with refractory tumor stage mycosis fungoides underwent allogeneic HLA-matched sibling transplantation with combined marrow and CD34-enriched peripheral blood stem cell transplantation after cytoreductive chemotherapy and total-body irradiation.
  • One patient was in complete remission for 9 months, followed by limited cutaneous recurrence.
  • Mild graft-vs-host disease and graft-vs-tumor effect have contained the recurring disease as a low-grade process.
  • CONCLUSIONS: Allogeneic hematopoietic stem cell transplantation has the potential for sustained remission and the possibility of cure for young patients with advanced and recalcitrant cutaneous T-cell lymphoma.
  • Even in the absence of complete remission, an allogeneic graft-vs-tumor effect may provide an immune mechanism to control the malignant T-cell process and alter the natural history of disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell, Cutaneous / pathology. Lymphoma, T-Cell, Cutaneous / therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Male. Mycosis Fungoides / pathology. Mycosis Fungoides / therapy. Remission Induction. Severity of Illness Index. Sezary Syndrome / pathology. Sezary Syndrome / therapy. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12374543.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


15. Tsatalas C, Martinis G, Margaritis D, Spanoudakis E, Kotsianidis I, Karpouzis A, Bourikas G: Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. J Eur Acad Dermatol Venereol; 2003 Jan;17(1):80-2
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin.
  • Advanced stage mycosis fungoides (MF) generally has a poor prognosis, and currently there is no standard treatment available.
  • Here we report the case of a young woman with recalcitrant tumour-stage MF (T3, stage IIb) whose disease was unresponsive to several therapeutic modalities, but who has showed sustained clinical response to pegylated liposomal doxorubucin.
  • The use of this drug in tumour-stage MF should be investigated further.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12602979.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL: [Treatment of cutaneous T-cell lymphomas with bexarotene]. Actas Dermosifiliogr; 2005 Dec;96(10):669-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of cutaneous T-cell lymphomas with bexarotene].
  • [Transliterated title] Tratamiento de linfomas cutáneos de células T con bexaroteno.
  • INTRODUCTION: The choice of treatment in cutaneous T-cell lymphomas (CTCLs) depends on the clinical stage of the disease and the patient's general condition.
  • To date, there is no curative treatment for this disease, and the objective is to control the symptoms and prevent the disease from progressing.
  • Bexarotene is an X receptor-specific retinoid with anti-tumor activity.
  • Its use as treatment for CTCLs refractory to at least one prior systemic therapy has been approved by the FDA.
  • PATIENTS AND METHODS: We carried out a descriptive study of 9 patients treated with bexarotene in the Lymphoma Unit of our department.
  • We analyzed the clinical characteristics of the patients and the efficacy of the treatment, and we collected data on the side effects that appeared.
  • RESULTS: The overall response to the treatment was 44.4% (4/9).
  • Tolerance to the treatment was good, and the most frequent side effects were hypertriglyceridemia, hypercholesterolemia and central hypothyroidism.
  • Bexarotene is an effective therapeutic option in this heterogeneous group of diseases.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. Tetrahydronaphthalenes / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Actas Dermosifiliogr. 2006 Mar;97(2):102
  • (PMID = 16476317.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


17. Gerena Lewis MA, Shukla R, Kleykamp B, Jazieh AR, Hainsworth J: A phase II trial of denileukin difititox-in previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7292

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of denileukin difititox-in previously treated, advanced non-small cell lung cancer (NSCLC).
  • : 7292 Background: Prior studies have shown that the interleukin-2 receptor (IL-2r) is expressed on lung cancer cells suggesting that an IL-2r targeted therapy may have a role in the management of NSCLC.
  • Denileukin diftitox, ONTAK®, is a chimeric protein that targets the cytocidal properties of diphtheria toxin to cells that express IL-2r and is approved for the treatment of cutaneous T-cell lymphoma.
  • In this study, we evaluate the potential benefit of ONTAK in the treatment of advanced NSCLC.
  • METHODS: This multi-center phase II clinical trial is open for enrollment of patients with ECOG PS 0-2 and Stage IIIB/IV NSCLC who have failed at least one prior chemotherapy regimen.
  • Radiographic evaluation of tumor response is performed every 2 cycles.
  • The mean number of prior treatment regimens is 2 (range 1-5).
  • Treatment-related Grade 3 toxicities included nausea (3), emesis (2), fever (2), fatigue (2), dehydration (2), edema (1), itching (1), pain at tumor site (1), flu-like symptoms (1), and headache (1).
  • Symptomatic capillary leak syndrome and treatment-related death were not encountered.
  • No patient was withdrawn due to treatment-related toxicity.
  • The median time to disease progression for all evaluable patients was 1.8 months (9 days-13 months) and the median overall survival was 4.3 months (2.7 weeks-15.5 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Giaccone G, Rajan A, Carter C, Kelly R, Berman A, Spittler J, Espinoza-Delgado I, Lee M, Trepel J, Loehrer P: Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy is used for advanced disease.
  • There is no established role of second-line therapy in patients with refractory or recurrent disease.
  • Belinostat is an HDAC inhibitor with activity in cutaneous and peripheral T cell lymphoma and is being investigated in several solid tumors.
  • METHODS: Patients with recurrent thymoma or thymic carcinoma, progressing after platinum-based chemotherapy were eligible.
  • Correlative markers of activity in blood and tumor were performed.
  • RESULTS: From December 07 to December 08, 22 patients have been accrued from 2 institutions; 12 patients were males, median age 52 (23-72), 14 thymomas and 8 thymic carcinomas, mean number of prior regimens 3.5 (1-10), 16 prior tumor resection and 3 myasthenia gravis.
  • Treatment was well tolerated, with nausea being the most common side effect and well controlled with prophylactic antiemetics.
  • CONCLUSIONS: The thymoma cohort has been expanded to the second stage of the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Boudova L, Kazakov DV, Jindra P, Sima R, Vanecek T, Kuntscher V, Vera V, Bouda J, Michal M: Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol; 2006 Aug;33(8):584-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman.
  • BACKGROUND: Cutaneous lymphomas co-expressing CD56 and CD30 are very rare.
  • They share a clinicopathological overlap with natural killer- (NK)/T-cell lymphomas and anaplastic large-cell lymphomas (ALCLs), two entities with widely disparate clinical behavior.
  • METHODS: We present a case of an immunocompetent 57-year-old Caucasian woman with a rapidly growing, angiodestructive and neuroinvasive primary cutaneous ALCL (PCALCL).
  • The partially ulcerated and pus-secreting tumor involved the forehead and scalp and was assessed as clinical stage IAE.
  • RESULTS: After chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), the patient achieved a complete remission.
  • Additionally, high-dose chemotherapy with autologous peripheral blood stem-cell transplantation was administered as a consolidation of complete remission, in which she has remained for 6 years.
  • CONCLUSIONS: This is the first CD30+ and CD56+ primary skin lymphoma to be reported on the head.
  • The presented case carries a remarkable combination of clinicopathological features of PCALCL and NK-/T-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, CD56 / analysis. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Forehead. Head and Neck Neoplasms / blood supply. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / immunology. Head and Neck Neoplasms / pathology. Histiocytes / cytology. Humans. Middle Aged. Neutrophils / cytology. Scalp / blood supply. Scalp / drug effects. Scalp / innervation. Scalp / pathology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919035.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD56
  •  go-up   go-down


20. Summers TA Jr, Rush W, Aguilera N, Lupton G: Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:25-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature.
  • Lennert lymphoma (LL), or the lymphoepithelioid variant of peripheral T-cell lymphoma, is an uncommon entity with rarely seen or reported presentations in the skin.
  • Cutaneous involvement of LL has been characterized by asymptomatic, non-ulcerated, red to violet papules, nodules and small plaques (less than 5 cm) on the trunk and extremities.
  • Key to the diagnosis of LL is the presence of epithelioid histiocytes and atypical small lymphoid cells without increased vascularity or epidermotropism.
  • Immunophenotyping shows a dense monoclonal T-cell population commonly associated with aberrant loss of T-cell-associated antigens.
  • T-cell receptor gene rearrangements are also identified.
  • Patients typically present with advanced stage and have a low 5-year survival.
  • Herein, we present a case of cutaneous involvement by LL at the time of initial presentation that persisted after initiation of chemotherapy and was finally verified as secondary cutaneous involvement of LL 1 year later histologically, immunophenotypically and by T-cell receptor gene rearrangement studies.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD / biosynthesis. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775391.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  • [Number-of-references] 18
  •  go-up   go-down


21. Onesti MG, Mazzocchi M, De Leo A, Scuderi N: T-cell lymphoma presenting as a rapidly enlarging tumor on the lower eyelid. Acta Chir Plast; 2005;47(3):65-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma presenting as a rapidly enlarging tumor on the lower eyelid.
  • Lymphoma or leukemia skin lesions as a secondary site of disease are quite common; however, to discover a cutaneous Hodgkin or non-Hodgkin lymphoma is very unusual.
  • To find a cutaneous T-cell lymphoma on the skin of the face is a rarity.
  • Because the condition is so rare and difficult to diagnose and treat, we report the case of a young man with a T-cell lymphoma with atypical and anaplastic cells on the lower eyelid.
  • The patient was treated with 4 cycles of chemotherapy, and radiotherapy, and the tumor was resolved after 6 weeks.
  • Our case was clinically suggestive of a rapidly enlarging malignant lymphoma on the eyelid.
  • If the lymphomas are detected at an early stage the prognosis for survival is favorable.
  • A few forms of treatment are possible, either surgical treatment, or radiotherapy and chemotherapy, where response to the treatment is better.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Eyelids. Humans. Male. Prednisone / therapeutic use. Radiotherapy. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173513.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. Parker SR, Solomon AR, Lane JE: A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma. J Am Acad Dermatol; 2008 Jul;59(1):157-61
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma.
  • We describe a patient who presented with Epstein-Barr virus-positive tumor-stage primary cutaneous lymphoma.
  • Tissue analysis revealed large tumor cells that were surface CD2- and CD3-positive; T-cell-restricted intracellular antigen-positive; CD56-, CD20-, and CD30-negative; and stained positively for Epstein-Barr virus.
  • Although the presence of rheumatoid arthritis and therapy with methotrexate are putative risk factors for the development of immune suppression-related and Epstein-Barr virus-related lymphomas, the vast majority of lymphomas in this setting are of B-cell origin, and rarely are these primary cutaneous in nature.
  • In addition, our patient's tumor displayed an unusual phenotype, with immunophenotypic features suggestive of an atypical natural killer-/T-cell lymphoma.
  • She has remained in complete remission 28 months since diagnosis.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis
  • [MeSH-minor] Administration, Oral. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Biopsy. Female. Humans. Killer Cells, Natural. Lymphocyte Subsets. Methotrexate / administration & dosage. Middle Aged. Skin / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468723.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol; 2003 Nov;49(5):873-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.
  • BACKGROUND: Although low-dose methotrexate has been used to treat mycosis fungoides for many years, documentation is very limited.
  • OBJECTIVE: Our purpose was to review our experience with methotrexate in the treatment of 69 patients with patch/plaque and tumor stage mycosis fungoides observed for up to 201 months.
  • Data are presented in terms of response rates and time to treatment failure.
  • RESULTS: The greatest number of patients (60) had patch/plaque stage T2 disease (>/=10% skin involved).
  • The median time to treatment failure was 15 months.
  • Only 1 of 7 patients with tumor stage disease responded.
  • Side effects caused treatment failure in 6 (9%) of the total cohort of 69 patients.
  • CONCLUSION: Low-dose methotrexate may be of value in the treatment of a subset of patients with patch/plaque mycosis fungoides resistant to other therapies.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Methotrexate / administration & dosage. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14576667.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol; 2000 Jan;42(1 Pt 1):40-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.
  • BACKGROUND: Pegylated liposomes are stable, long-circulating carriers useful for delivering doxorubicin to tumor sites with a lower toxicity than the free drug.
  • Free doxorubicin is used in several treatment protocols for non-Hodgkin's lymphoma.
  • Although pegylated liposomal doxorubicin is currently used in the treatment of Kaposi's sarcoma, no data are available for tumors, such as primary cutaneous T-cell lymphomas (CTCLs).
  • Six patients (1 woman and 5 men) aged 59 to 78 years with relapsing or recalcitrant CTCL of the mycosis fungoides type, stage (Ib/IIb), were treated with pegylated liposomal doxorubicin to induce a clinical response.
  • The drug was administered at a dosage of 20 mg m(-2) once a month.
  • There was no need of additional therapy because of side effects.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Carriers. Female. Humans. Infusions, Intravenous. Liposomes. Male. Middle Aged. Pilot Projects. Polyethylene Glycols. Prospective Studies. Recurrence

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2001 Jan;44(1):149-50 [11148501.001]
  • (PMID = 10607318.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N: Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):51-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
  • PURPOSE: The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL).
  • RESULTS: Two patients with CD30+ anaplastic large T-cell lymphoma and 31 with mycosis fungoides (stage IB [T2, n = 2], stage IIA [T2, n = 1], stage IIB [T3, n = 13], stage IVA [T3 N3, n = 3; T4b2, n = 2; T4b2 N3, n = 2], and stage IVB [T4b2 N1, n = 6; T4 N3b2 M1, n = 1; T3 N3 M1, n = 1]) had received a median of 5 previous therapies (range, 1-13 therapies).
  • Seven of 13 patients with mycosis fungoides (T3) responded, 10 had tumor burden reductions, and 8 of 11 patients with Sezary syndrome responded.
  • Increased hepatic transaminases (n = 4), mucositis (n = 3), lethargy (n = 7), fever (n = 8), cutaneous hyperpigmentation (n = 6), infusion-related maculopapular rash (n = 1), and radiation recall (n = 1) were also seen.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Mycosis Fungoides / complications. Receptors, Interleukin-2 / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879770.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R: Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol; 2004 Aug;51(2):200-4
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
  • BACKGROUND: Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL).
  • Patients with improvement after two months could be continued on treatment.
  • RESULTS: Twelve out of the 13 patients enrolled on study were evaluable (Stage I-IIA, 3 patients; Stage IIB-IV disease, 9 patients).
  • The median number of previous therapies was 7 (range, 3-12).
  • Etanercept induced partial remission in one patient (8%) and minor response in one patient (8%), both of whom had Stage IB disease.
  • [MeSH-major] Immunoglobulin G / administration & dosage. Lymphoma, T-Cell, Cutaneous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Receptors, Tumor Necrosis Factor / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Etanercept. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15280837.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


27. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol; 2010 Oct 10;28(29):4485-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
  • PURPOSE: The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).
  • PATIENTS AND METHODS: This international, pivotal, single-arm, open-label, phase II study was conducted in patients with stage IB to IVA CTCL who had received one or more prior systemic therapies.
  • Response was determined by a composite assessment of total tumor burden including cutaneous disease, lymph node involvement, and blood (Sézary cells).
  • Most patients (71%) had advanced stage disease (≥ IIB).
  • The median time to response was 2 months, and the median duration of response was 15 months.
  • Drug-related adverse events were generally mild and consisted mainly of GI disturbances and asthenic conditions.
  • CONCLUSION: Romidepsin has significant and sustainable single-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an important therapeutic option for treatment refractory CTCL.
  • [MeSH-major] Depsipeptides / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin / drug effects. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Asthenia / chemically induced. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Prospective Studies. Treatment Outcome. Vomiting / chemically induced


28. Wollina U, Graefe T, Kaatz M: Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol; 2001 Feb;127(2):128-34
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up.
  • PURPOSE: Pegylated liposomal doxorubicin (PEG-DOXO) was found to be effective in primary cutaneous T-cell lymphomas (CTCL).
  • METHODS: Ten patients (one female, nine male) aged 50-78 years (mean 66.7 years) with relapsing or recalcitrant CTCL, stage I b (n = 3), II a (2), II b (3), IV a (1), and IV b (1) were treated with PEG-DOXO 20 mg m(-2) once a month with an upper limit of 400 mg or eight infusions to induce a clinical response.
  • Four patients (stage I b and II b) achieved 12-19 months of disease-free survival.
  • One patient free of relapse died after 12 months because of pulmonary embolism not related to disease or treatment.
  • Another patient died 1 month after a second course of PEG-DOXO in an advanced tumor stage of CTCL.
  • The most frequent side effects of treatment were anemia and lymphopenia without the need of supportive treatment or dose-reduction.
  • Only one patient developed toxicity of grade 4 (anemia).
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, T-Cell, Cutaneous / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216914.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / Surface-Active Agents; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


29. Li N, Kim JH, Glusac EJ: Brainstem involvement by mycosis fungoides in a patient with large-cell transformation: a case report and review of literature. J Cutan Pathol; 2003 May;30(5):326-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem involvement by mycosis fungoides in a patient with large-cell transformation: a case report and review of literature.
  • BACKGROUND: Central nervous system (CNS) involvement by mycosis fungoides (MF) is rare.
  • RESULTS: A 71-year-old female with long-standing MF developed lymphomatous CNS involvement 10 years after the diagnosis of tumor stage MF.
  • At this time, the patient presented with a transient episode of garbled speech followed by generalized weakness.
  • Computerized tomography scan (CT scan) and magnetic resonance imaging scan (MRI scan) of the head revealed a subcortical lesion in the left temporo-frontal lobe.
  • Cerebrospinal fluid (CSF) examination showed atypical T cells, and brain biopsy confirmed parenchymal involvement by T-cell lymphoma.
  • Meanwhile, a biopsy of a skin lesion showed large-cell transformation.
  • No lymph node or other systemic involvement was noted at this time, and the patient was treated with chemotherapy.
  • Twelve months later, the patient developed recurrent CNS lymphoma with multiple organ involvement and expired soon thereafter.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Mycosis Fungoides / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753174.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Bladon J, Taylor P: Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo. J Clin Apher; 2002;17(4):177-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracorporeal photopheresis (ECP) has been shown to be clinically effective in the treatment of many T cell-mediated conditions.
  • We were interested to determine what influence ECP has on pro-inflammatory cytokine secretion at this early pre-infusion stage.
  • Samples from 6 cutaneous T cell lymphoma (CTCL) and 5 graft versus host disease (GvHD) patients were taken pre ECP and immediately post ECP, prior to re-infusion.
  • Following separation, the PBMCs were added to a cell culture medium and stimulated with PMA, Ionomycin, and Brefeldin A for 6 hours.
  • Using flow cytometry, intracellular cytokine expression of IFNgamma and TNFalpha was determined in the T cell population.
  • For both patient groups, the number of IFNgamma-expressing T cells fell significantly at re-infusion, whilst both T cell- and monocyte-expressing TNFalpha levels were reduced at re-infusion.
  • However, the reduction in the number of IFNgamma- and TNFalpha-expressing mononuclear cells means, at this early stage, it is unlikely that these cytokines assist in the removal of the malignant Th2 cells present in CTCL.
  • [MeSH-minor] Case-Control Studies. Down-Regulation. Graft vs Host Disease / immunology. Graft vs Host Disease / pathology. Humans. Inflammation Mediators. Interferon-gamma / analysis. Leukocyte Count. Lymphocyte Activation / drug effects. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Lymphoma, T-Cell, Cutaneous / therapy. T-Lymphocytes / pathology. T-Lymphocytes / secretion. Tumor Necrosis Factor-alpha / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12494410.001).
  • [ISSN] 0733-2459
  • [Journal-full-title] Journal of clinical apheresis
  • [ISO-abbreviation] J Clin Apher
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Inflammation Mediators; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


31. Grange F: [Skin cancer: what's new in clinical research?]. Ann Dermatol Venereol; 2007 Dec;134 Suppl 1:8S53-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review of the recent literature, we selected epidemiological, clinical, and therapeutic data published between October 2006 and September 2007.
  • New epidemiological data have been provided regarding the incidence of different types of skin cancers, the effect of certain risk factors or drug or food protective factors, the overall improvement of survival in melanoma, the epidemiological, clinical, and/or therapeutic particularities of rapidely growing melanomas and thick melanomas, and the relations between sun exposure, skin cancers, and other solid tumors.
  • New prognostic studies in melanoma have improved the evaluation of prognosis in specific situations such as thin melanoma, acrolentiginous melanoma, and melanoma with positive sentinel lymph nodes (depending on the type of positivity) or negative sentinel lymph nodes.
  • Clinical trials evaluating new therapeutic approaches in stage III and IV melanoma are going on.
  • Several studies confirmed the clinical benefit of adjuvant irradiation on the tumor site in Merkel cell carcinoma.
  • New treatments are being studied or have been approved in refractory forms of cutaneous T-cell lymphoma and in inoperable forms of squamous cell carcinoma and dermatofibrosarcoma protuberans.
  • [MeSH-major] Biomedical Research / trends. Carcinoma / therapy. Dermatofibrosarcoma / therapy. Lymphoma, T-Cell, Cutaneous / therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / therapy. Evidence-Based Medicine. France / epidemiology. Humans. Incidence. Interferons / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675141.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  • [Number-of-references] 66
  •  go-up   go-down


32. Akita Y, Watanabe D, Yanagishita T, Kuhara T, Kawamura C, Masuda Y, Kawada M, Nakaseko H, Tamada Y, Matsumoto Y: The effect of psoralen plus ultraviolet A in vitro in HUT-78 enhances by 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed; 2007 Apr-Jun;23(2-3):95-7
Hazardous Substances Data Bank. 8-METHOXYPSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sezary syndrome and mycosis fungoides are forms of cutaneous T-cell lymphoma, and in the early stage of these diseases psoralen plus ultraviolet A (PUVA) is one of the treatments of choice.
  • Photodynamic therapy using 5-aminolevulinic acid (ALA-PDT) is an effective, non-invasive, and safe treatment for most superficial skin cancers.
  • In order to obtain greater efficacy of PUVA, we investigated the synergistic anti-tumor effects of ALA-PDT and PUVA using 8-methoxypsoralen (8-MOP) and a UVA lamp.
  • METHODS: The in vitro effects of PUVA and ALA-PDT and their combination in HUT-78 cell line from human SS were determined by MTT assay.
  • RESULTS: In our results, cell proliferation compared with controls was inhibited to 53.2% with UVA alone, 52.3% with 1 microM 8-MOP, 43.8% with 100 microM ALA, and 19.2% with combined 8-MOP and ALA.
  • CONCLUSION: Combined use of ALA and PUVA using 8-MOP and UVA lamps, which are widespread in Japan, had a strong anti-tumor effect in vitro.
  • Combined treatment with ALA-PDT and PUVA using a UVA lamp appears to have a strong treatment effect.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Methoxsalen / administration & dosage. PUVA Therapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor / drug effects. Cell Line, Tumor / radiation effects. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. Drug Synergism. Humans. Mycosis Fungoides / drug therapy. Mycosis Fungoides / pathology. Sezary Syndrome / drug therapy. Sezary Syndrome / pathology. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523931.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


33. Assaf C: Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides. Dermatol Clin; 2008 Jan;26 Suppl 1:21-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Recombinant Fusion Proteins / therapeutic use

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405182.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


34. Markham T, Sheahan K, Collins P: Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol; 2001 Jun;144(6):1262-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides.
  • [MeSH-major] Mycosis Fungoides / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aminolevulinic Acid / therapeutic use. Humans. Male. Photosensitizing Agents / therapeutic use

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11422054.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


35. Amitay-Laish I, David M, Hodak E: Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides. J Am Acad Dermatol; 2009 Aug;61(2):361-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
  • [MeSH-major] Mycosis Fungoides / therapy. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / therapy. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Biopsy, Needle. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Retreatment. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Am Acad Dermatol. 2005 Jun;52(6):991-6 [15928617.001]
  • (PMID = 19615550.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down






Advertisement